Launch of generic version of Lipitor may be delayed

Article

Pfizer hopes to stave off the genericization of Lipitor by a year via a deal with Ranbaxy.

Originally, Lipitor (atorvastatin, Pfizer), the No. 1 selling drug in the United States by dollars, was supposed to go off patent in 2010. But under a new deal Pfizer just reached with Ranbaxy, the drug will be launched by the Indian drugmaker as a generic starting Nov. 30, 2011, instead. In return for delaying the launch, Ranbaxy will be given some concessions, such as getting to sell a generic version of Pfizer’s Caduet (amlodipine besylate/atorvastatin calcium) seven years before its patent expiration. The Pfizer-Ranbaxy deal still must be approved by federal regulators.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Dr. Charles Lee
Dr. Charles Lee
Dr. Charles Lee
© 2024 MJH Life Sciences

All rights reserved.